InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the detailed record of transactions filed by Pott, Amy. Officer active across 2 companies, notably enGene Therapeutics Inc.. Aggregated, 6 disclosures have been published. History available since 16 June 2026. The latest transaction was filed on 25 June 2026 (50 - Grant of options). Regulator: SEDI. All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations
Amy Pott is a declarant linked to Eupraxia Pharmaceuticals Inc. and enGene Therapeutics Inc. The record includes 6 filings in total, and for the 6 sampled most recent filings, the period runs from 2026-06-19 to 2026-06-30. The total buy amount is EUR 0 and the total sell amount is EUR 0, with the modal transaction nature shown as 00 - Opening Balance-Initial SEDI Report.